The Greater Cannabis Company, Inc. (GCAN)

OTCMKTS · Delayed Price · Currency is USD
0.1321
-0.0429 (-24.51%)
At close: Mar 4, 2026
Market Cap165.36K -58.9%
Revenue (ttm)n/a
Net Income-712.72K
EPS-0.98
Shares Out944.94K
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume44,034
Average Volume11,249
Open0.1600
Previous Close0.1750
Day's Range0.1321 - 0.2172
52-Week Range0.0360 - 3.6000
Beta0.94
RSI45.32
Earnings DateApr 2, 2026

About GCAN

The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease, and other neuropsychiatric disorders. The company was founded in 2014 and is based in Baltimore, Maryland. [Read more]

Sector Healthcare
Founded 2014
Employees 1
Stock Exchange OTCMKTS
Ticker Symbol GCAN
Full Company Profile

Financial Performance

Financial Statements